Company

RNAF III Becomes a Strategic Partner in ATCO Pharma to Strengthen Manufacturing and Accelerate Regional and International Expansion

The transaction establishes joint control and brings fresh growth capital to the human and animal health businesses, with Dr. Ahmed Abouelnaga continuing as CEO.

Cairo, October 21, 2026 – ATCO Pharma, a leading Egyptian pharmaceutical group in human and animal health, today announced the signing of definitive agreements for RNAF III, North Africa Fund III, managed by private equity firm RMBV, to become a strategic partner in ATCO. The transaction is designed to accelerate the company’s growth and its regional and international expansion, and to strengthen the manufacturing and competitive capabilities of a business founded four decades ago.

Under the agreements, RMBV will invest new capital to support ATCO Pharma’s growth through a structure combining newly issued shares with the purchase of existing shares. This provides the company with additional capital and establishes joint control among the partners upon closing, while preserving continuity of the current executive management.

The partnership supports ATCO Pharma’s strategic evolution into a regional pharmaceutical platform with an international presence. The company will expand its portfolio of human and veterinary products, accelerate research and development and new product launches, strengthen its manufacturing capabilities, and take its brands into new markets across the region and beyond.

The transaction is also RMBV’s first investment in Egypt’s veterinary medicines sector, extending its healthcare portfolio and opening the door to growth opportunities across both human and animal health.

Dr. Ahmed Mostafa Abouelnaga will continue as Chief Executive Officer of ATCO Pharma, with the current management team continuing to lead operations and execute the company’s strategy, ensuring business continuity and building on its accumulated institutional expertise.

Zilla Capital acted as exclusive financial advisor to ATCO Pharma. Completion of the transaction remains subject to customary conditions, including approval from the Egyptian Competition Authority.

Dr. Ahmed Abouelnaga: This is not an exit. It accelerates our growth strategy.

Dr. Ahmed Mostafa Abouelnaga, CEO of ATCO Pharma, said the arrival of RMBV as a strategic partner marks a new chapter for the company, built on four decades of expertise and excellence in pharmaceuticals and a strong industrial and commercial base in Egypt.

“Building on 40 years of excellence and a solid foundation in Egypt, ATCO is entering a new chapter with an ambitious vision: to become a leading regional and global player in human and animal health. Together with RMBV, we will seize new opportunities, accelerate strategic investments, drive innovation and expand beyond our borders, combining ATCO’s strengths with RMBV’s international experience.”

He stressed that the partnership is not an exit for the founders, but a step to accelerate the delivery of the company’s long-term strategy: “This is not an exit. It is an acceleration of our ambitions. Our people, our values and our commitments remain unchanged, and the current management team will continue to lead ATCO into this promising new phase of growth.”

Dr. Mostafa Abouelnaga: The partnership builds on four decades of industrial growth.

Dr. Mostafa Abouelnaga, Co-Founder and Chairman of ATCO Pharma, said that welcoming RMBV as a long-term strategic partner is a natural continuation of the company’s journey since 1986, and reflects the strength of the industrial and institutional foundations built over four decades.

“When we founded ATCO in 1986, our ambition was to build an Egyptian pharmaceutical company grounded in quality, integrity and a deep commitment to patients and to improving animal health. Today, four decades on, we welcome RMBV as a long-term partner. It is a natural next step in this journey and a clear affirmation of what our team has built.”

He expressed confidence that the partnership will strengthen the values on which the company was founded, while providing the resources, capabilities and reach to realize its full potential and compete and expand in its target markets.

Eng. Mohamed Abouelnaga: Our goal is to become an institutional regional platform.

Eng. Mohamed Abouelnaga, Co-Founder and Vice Chairman of ATCO Pharma, said the partnership is an important milestone in the company’s evolution from a family-founded business into an institutional regional pharmaceutical platform, equipped with the operational and manufacturing capabilities needed for sustainable expansion.

He noted that sustained investment in manufacturing capacity and quality systems, together with a pipeline of products under development, has built a strong industrial base ready for its next phase of growth.

“This partnership is an important step in ATCO’s evolution from a family-founded company into an institutional regional platform. Together with RMBV, we will build on this foundation to strengthen our position in Egypt and internationally.”

Partner perspectives

Ahmed Badr El-Din, Managing Partner at RMBV, said: “ATCO combines the vision of its founders with a strong management team and proven manufacturing and commercial capabilities. Animal health is a cornerstone of food security, and we are proud to partner with the founders and their team to build a leading regional platform in veterinary and specialty human medicines.”

Mostafa El-Shenity, Co-Founder and Co-CEO of Zilla Capital, said: “Founder-led companies are the backbone of Egypt’s pharmaceutical industry, and ATCO is among its strongest. What distinguishes this transaction is the alignment between a founder who built a leading company from the ground up and an investor who shares his conviction in its growth potential. We believe it is a model for how founder-led companies in the region can scale without losing what made them successful.”

A New Phase of Growth and Investment in Pharmaceuticals

The partnership reflects ATCO Pharma’s drive to strengthen its competitiveness and expand beyond the domestic market, leveraging the complementarity between its industrial and commercial expertise and the international network and experience of its new investment partner.

Once the transaction closes and the required approvals are obtained, it is expected to create additional opportunities to broaden the product portfolio, increase investment in growth and innovation, and deepen the company’s presence in international markets.

The partnership also highlights the importance of attracting institutional capital to Egypt’s pharmaceutical industry, and its role in helping established local companies with strong industrial foundations evolve into regional platforms able to compete and expand globally.

About ATCO Pharma

Founded in 1986 by Dr. Mostafa Abouelnaga and Eng. Mohamed Abouelnaga, ATCO is a leading Egyptian pharmaceutical group operating in human and animal health. The group runs a modern manufacturing facility that adheres to international pharmaceutical standards, ensuring high levels of product quality and safety. Its portfolio includes more than 150 pharmaceutical products, spanning veterinary medicines and feed additives as well as human medicines such as Forfluzin and Tosistop. ATCO exports to more than 10 countries, including Saudi Arabia and Nepal, reflecting its growing international presence. Its R&D team is also advancing more than 160 products under registration and development, supporting the continued expansion of its portfolio.

 

Company